Potential biomarkers in breast cancer drug development: application of the biomarker qualification evidentiary framework
- 15 March 2024
- journal article
- review article
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 18 (6) , 265-277
Abstract
Breast cancer treatments have evolved rapidly, and clinically meaningful biomarkers have been used to guide therapy. These biomarkers hold utility within the drug development process to increase th...Keywords
Funding Information
- Daiichi Sankyo Company
This publication has 51 references indexed in Scilit:
- Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survivalAnnals of Oncology, 2020
- Association of Circulating Tumor DNA With Disease-Free Survival in Breast CancerJAMA Network Open, 2020
- Combined SOX10 GATA3 is most sensitive in detecting primary and metastatic breast cancers: a comparative study of breast markers in multiple tumorsBreast Cancer Research and Treatment, 2020
- Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test resultsThe Breast, 2020
- Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypesJournal of Cancer Research and Clinical Oncology, 2019
- MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor ModulatorsThe Breast, 2019
- Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patientsBreast Cancer Research and Treatment, 2018
- Ki-67: more than a proliferation markerChromosoma, 2018
- MicroRNA Profile in Response to Doxorubicin Treatment in Breast CancerJournal of Cellular Biochemistry, 2015
- Prevalence and Costs of Skin Cancer Treatment in the U.S., 2002−2006 and 2007−2011American Journal of Preventive Medicine, 2015